Pirfenidone as a Pleiotropic Antifibrotic Agent in Metabolic Steatohepatitis: From Mechanisms to Clinical Evidence

Key Points

• Pirfenidone demonstrates antifibrotic effects in metabolic steatohepatitis, which could mitigate liver damage and fibrosis.
• The study highlights the diverse mechanisms underlying the efficacy of pirfenidone, emphasizing its pleiotropic nature.
• Assessment using existing clinical evidence shows significant pathways and biomarkers involved in metabolic steatohepatitis treatment.
• Findings may enable new therapeutic strategies targeting complex metabolic liver diseases with less adverse effects.